JP7738007B2 - Ｔ細胞受容体 - Google Patents

Ｔ細胞受容体

Info

Publication number
JP7738007B2
JP7738007B2 JP2022558271A JP2022558271A JP7738007B2 JP 7738007 B2 JP7738007 B2 JP 7738007B2 JP 2022558271 A JP2022558271 A JP 2022558271A JP 2022558271 A JP2022558271 A JP 2022558271A JP 7738007 B2 JP7738007 B2 JP 7738007B2
Authority
JP
Japan
Prior art keywords
tcr
amino acid
chain
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022558271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519868A (ja
JPWO2021195503A5 (https=
JP2023519868A5 (https=
Inventor
ジャスディープ マン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2023519868A publication Critical patent/JP2023519868A/ja
Publication of JPWO2021195503A5 publication Critical patent/JPWO2021195503A5/ja
Publication of JP2023519868A5 publication Critical patent/JP2023519868A5/ja
Priority to JP2025144528A priority Critical patent/JP2025172113A/ja
Application granted granted Critical
Publication of JP7738007B2 publication Critical patent/JP7738007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022558271A 2020-03-27 2021-03-26 Ｔ細胞受容体 Active JP7738007B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025144528A JP2025172113A (ja) 2020-03-27 2025-09-01 Ｔ細胞受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000800P 2020-03-27 2020-03-27
US63/000,800 2020-03-27
PCT/US2021/024370 WO2021195503A1 (en) 2020-03-27 2021-03-26 T cell receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025144528A Division JP2025172113A (ja) 2020-03-27 2025-09-01 Ｔ細胞受容体

Publications (4)

Publication Number Publication Date
JP2023519868A JP2023519868A (ja) 2023-05-15
JPWO2021195503A5 JPWO2021195503A5 (https=) 2024-04-05
JP2023519868A5 JP2023519868A5 (https=) 2024-04-05
JP7738007B2 true JP7738007B2 (ja) 2025-09-11

Family

ID=77890524

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022558271A Active JP7738007B2 (ja) 2020-03-27 2021-03-26 Ｔ細胞受容体
JP2025144528A Pending JP2025172113A (ja) 2020-03-27 2025-09-01 Ｔ細胞受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025144528A Pending JP2025172113A (ja) 2020-03-27 2025-09-01 Ｔ細胞受容体

Country Status (11)

Country Link
US (1) US20230124640A1 (https=)
EP (1) EP4126924A4 (https=)
JP (2) JP7738007B2 (https=)
KR (1) KR20220160040A (https=)
CN (1) CN115485294A (https=)
AU (1) AU2021244594A1 (https=)
BR (1) BR112022019380A2 (https=)
CA (1) CA3177181A1 (https=)
IL (1) IL296827A (https=)
MX (1) MX2022012062A (https=)
WO (1) WO2021195503A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3225252A1 (en) 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies
CN119546328A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
CN117003855B (zh) * 2023-09-20 2024-02-23 广州市老人院 一种t细胞受体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102876715A (zh) 2012-09-05 2013-01-16 南方医科大学 一种用于结核/hiv共感染基因治疗的逆转录病毒载体及其应用
CN102911267A (zh) 2012-09-19 2013-02-06 南方医科大学 一种结核/hiv抗原肽双特异性tcr、其重组逆转录病毒载体与应用
US20190169261A1 (en) 2016-06-17 2019-06-06 Medigene Immunotherapies Gmbh T cell receptors and uses thereof
JP2022527635A (ja) 2019-03-27 2022-06-02 メディジーン イミュノセラピーズ ゲーエムベーハー Ｍａｇｅ ａ４ ｔ細胞受容体
JP2022532557A (ja) 2019-05-08 2022-07-15 メディジーン イミュノテラピーズ ゲーエムベーハー 操作されたｔ細胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361794B2 (en) * 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
LT3424947T (lt) * 2011-10-28 2021-03-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos t ląstelių receptorių pelės
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
BR112020006643A2 (pt) * 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
CA3225252A1 (en) * 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102876715A (zh) 2012-09-05 2013-01-16 南方医科大学 一种用于结核/hiv共感染基因治疗的逆转录病毒载体及其应用
CN102911267A (zh) 2012-09-19 2013-02-06 南方医科大学 一种结核/hiv抗原肽双特异性tcr、其重组逆转录病毒载体与应用
US20190169261A1 (en) 2016-06-17 2019-06-06 Medigene Immunotherapies Gmbh T cell receptors and uses thereof
JP2022527635A (ja) 2019-03-27 2022-06-02 メディジーン イミュノセラピーズ ゲーエムベーハー Ｍａｇｅ ａ４ ｔ細胞受容体
JP2022532557A (ja) 2019-05-08 2022-07-15 メディジーン イミュノテラピーズ ゲーエムベーハー 操作されたｔ細胞

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAGA-FRIEDMAN, A et al.，Incorporation of Transmembrane Hydrophobic Mutations in the TCR Enhance Its Surface Expression and T Cell Functional Avidity，The Journal of Immunology，2012年，Vol. 188, No. 11，pp. 5538-5546
SOMMERMEYER, D et al.，Minimal Amino Acid Exchange in Human TCR Constant Regions Fosters Improved Function of TCR Gene-Modified T Cells，The Journal of Immunology，2010年，Vol. 184, No. 11，pp. 6223-6231

Also Published As

Publication number Publication date
KR20220160040A (ko) 2022-12-05
IL296827A (en) 2022-11-01
CN115485294A (zh) 2022-12-16
CA3177181A1 (en) 2021-09-30
BR112022019380A2 (pt) 2022-11-29
JP2025172113A (ja) 2025-11-20
EP4126924A1 (en) 2023-02-08
EP4126924A4 (en) 2024-04-24
JP2023519868A (ja) 2023-05-15
AU2021244594A1 (en) 2022-12-01
US20230124640A1 (en) 2023-04-20
MX2022012062A (es) 2023-01-11
WO2021195503A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
JP7723887B2 (ja) 操作されたｔ細胞
JP2025172113A (ja) Ｔ細胞受容体
JP2022537159A (ja) 癌を治療するための組成物および方法
JP7765291B2 (ja) Ｃｄ３３標的免疫療法
EP4038103A1 (en) Dimerizing agent regulated immunoreceptor complexes
AU2019397152A1 (en) Dimerizing agent regulated immunoreceptor complexes
JP2024525727A (ja) 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
JP2025081414A (ja) Ｃｌｌ－１標的免疫療法
JP2021506271A (ja) Ｄａｒｉｃインターロイキン受容体
KR20230053650A (ko) Bcma 키메라 항원 수용체
CN115397864A (zh) 经修饰的ccr多肽和其用途
AU2020267559A1 (en) CD123 targeted immunotherapies
EA052725B1 (ru) Т-клеточные рецепторы
EA049270B1 (ru) Сконструированные т-клетки

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240326

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250901

R150 Certificate of patent or registration of utility model

Ref document number: 7738007

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150